.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Merck
Argus Health
Moodys
McKesson
Chinese Patent Office
US Department of Justice
Cantor Fitzgerald
Farmers Insurance
McKinsey

Generated: December 13, 2017

DrugPatentWatch Database Preview

ARRANON Drug Profile

« Back to Dashboard

Which patents cover Arranon, and what generic alternatives are available?

Arranon is a drug marketed by Novartis Pharms Corp and is included in one NDA. There is one patent protecting this drug.

This drug has forty-three patent family members in twenty-eight countries and eight supplementary protection certificates in seven countries.

The generic ingredient in ARRANON is nelarabine. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nelarabine profile page.
Drug patent expirations by year for ARRANON

Pharmacology for ARRANON

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms CorpARRANONnelarabineINJECTABLE;IV (INFUSION)021877-001Oct 28, 2005RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ARRANON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms CorpARRANONnelarabineINJECTABLE;IV (INFUSION)021877-001Oct 28, 2005► Subscribe► Subscribe
Novartis Pharms CorpARRANONnelarabineINJECTABLE;IV (INFUSION)021877-001Oct 28, 2005► Subscribe► Subscribe
Novartis Pharms CorpARRANONnelarabineINJECTABLE;IV (INFUSION)021877-001Oct 28, 2005► Subscribe► Subscribe
Novartis Pharms CorpARRANONnelarabineINJECTABLE;IV (INFUSION)021877-001Oct 28, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ARRANON

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,539,098 5'-O-propionyl and 5'-O-butyryl esters of 2-amino-6-methoxy-9-(.beta.-D-arabinofuranosyl)-9H-purine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ARRANON

Country Document Number Estimated Expiration
European Patent Office0294114► Subscribe
Norway882357► Subscribe
Australia622403► Subscribe
Cyprus2001► Subscribe
Australia1671888► Subscribe
Israel86531► Subscribe
Czechoslovakia8803635► Subscribe
Luxembourg91370► Subscribe
Germany122008000003► Subscribe
Poland272729► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ARRANON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00302Netherlands► SubscribePRODUCT NAME: NELARABINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR BAAR ZOUT, ETHER OF ESTER; REGISTRATION NO/DATE: EU/1/07/403/001 20070822
C/GB08/006United Kingdom► SubscribePRODUCT NAME: NELARABINE, OR ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ETHERS, ESTERS, OR SALTS OF SUCH ESTERS THEREOF.; REGISTERED: UK EU/1/07/403/001 20070822
07C/063Belgium► SubscribePRODUCT NAME: NELARABINE; REGISTRATION NO/DATE: EU/1/07/403/001 20070823
0294114/01Switzerland► SubscribePRODUCT NAME: NELARABIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57899 08.08.2007
0302Netherlands► Subscribe300302, 20080527, EXPIRES: 20130526
/2007Austria► SubscribePRODUCT NAME: NELARABINE; REGISTRATION NO/DATE: EU/1/07/403/001 20070822
C0058France► SubscribePRODUCT NAME: NELARABINE, OU L?UN DE SES DERIVES PHYSIOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/07/403/001 DU 20070822; REGISTRATION NO/DATE AT EEC: EU/1/07/403/001 DU 20070822
370Luxembourg► Subscribe91370, EXPIRES: 20130527
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Deloitte
Moodys
Harvard Business School
US Department of Justice
Medtronic
Accenture
Novartis
Merck
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot